[Correspondence] Neoadjuvant chemotherapy in oesophageal adenocarcinoma

Alderson and colleagues should be congratulated for the MRC OE05 trial,1 randomly assigning almost 900 patients with locally advanced, resectable oesophageal adenocarcinoma to cisplatin and fluorouracil (CF) for two cycles, or to epirubicin, cisplatin, and capecitabine (ECX) for four cycles, followed by surgery in both groups. The trial failed to demonstrate a significant overall survival improvement with ECX (hazard ratio 0·90, 95% CI 0·77–1·05; p=0·19).

http://ift.tt/2h1Vhk9